The Medtronic Harmony Transcatheter Pulmonary Valve (TPV) System. It is first in the world non-surgical heart valve to treat pediatric and adult patients with a native or surgically-repaired right ventricular outflow tract (RVOT) to stop severe pulmonary valve regurgitation caused by congenital heart disease.
Feature | Structural Heart | By Dave Fornell, Editor

March 26, 2021 — Today, the U.S. Food and Drug Administration (FDA) cleared the Medtronic Harmony Transcatheter ...

Home March 26, 2021
Home
The March April 2021 issue of DAIC, Diagnostic and Interventional Cardiology magazine, Dave Fornell is the editor.
Feature

View the March-April 2021 digital edition of Diagnostic and Interventional Cardiology (DAIC) magazine, including links ...

Home March 26, 2021
Home
Virtual tour views of a University of Colorado cath lab during a CTO procedure (top left), the new robotic EP lab at Banner Health (top right), a bi-plane EP/cath combo lab at Baylor Heart Hospital Dallas (bottom left, and an ECMO procedure at Tufts Medical Center cath lab. Photos by Dave Fornell
Feature

There is a lot of interest in how other hospitals organize and equip their cardiac cath labs and electrophysiology (EP) ...

Home March 25, 2021
Home
News | Congenital Heart

March 24, 2021 — Congenital heart disease (CHD) affects six out of 1,000 babies born in the U.S. each year and is often ...

Home March 24, 2021
Home
News | Heart Failure

March 24, 2021 — Endotronix Inc., a digital health and medical technology company working on advancements in treating of ...

Home March 24, 2021
Home
Videos | Structural Heart

Interview with Scott E. Kasner, M.D., who served as the principle investigator for the Gore Cardioform REDUCE trial, and ...

Home March 23, 2021
Home
News | EP Lab

March 23, 2021 — Researchers at Columbia University are using cardiac ultrasound to improve the critical need to ...

Home March 23, 2021
Home
News | CT Angiography (CTA)

March 23, 2021 — Researchers at the Karolinska Institute in Stockholm, Sweden, have published the first-of-its-kind ...

Home March 23, 2021
Home
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients
Feature | Antiplatelet and Anticoagulation Therapies | By Dave Fornell, Editor

A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal ...

Home March 22, 2021
Home
Videos | Ventricular Assist Devices (VAD)

Surgeons at Penn State Heart and Vascular Institute were the second group in the nation to implant a newly-designed ...

Home March 22, 2021
Home
News | Heart Valve Technology

March 18, 2020 — A groundbreaking new study led by University of Minnesota Twin Cities researchers from both the College ...

Home March 18, 2021
Home
News | Point-of-Care Ultrasound (POCUS)

March 18, 2021 — GE Healthcare this week unveiled Vscan Air, a cutting-edge, wireless pocket-sized ultrasound that ...

Home March 18, 2021
Home
News | Interventional Radiology

March 18, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's TheraSphere Y-90 Glass ...

Home March 18, 2021
Home
Integrating data from an array of implantable EP devices from different vendors can be difficult or require disconnected silos of data for different vendors. One solution that was recently introduced to integrate data from various vendors is the Optimize EP software, which allows viewing data from all device vendors in one platform to streamline workflows.
Feature | EP Lab | By Maninder Bedi, M.D.

A few weeks ago, a patient of mine experienced a cardiac event — his heart stopped. Completely. However, his implantable ...

Home March 17, 2021
Home
News | Coronavirus (COVID-19)

March 17, 2021 — Around 50% of patients who have been hospitalized with severe COVID-19 (SARS-CoV-2) and have damage to ...

Home March 17, 2021
Home
Subscribe Now